Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-04-02 Sale | 2024-04-03 5:00 pm | Verve Therapeutics Inc. | VERV | Nickerson Joan Chief Administrative Officer | 1,514 | $8.24 | $12,475 | 18,604 (Direct) | View |
| 2023-12-01 Purchase | 2023-12-05 4:30 pm | Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner | 1,800,000 | $10 | $18,000,000 | 12,168,489 (Indirect) | View |
| 2023-11-29 Sale | 2023-12-01 4:30 pm | Verve Therapeutics Inc. | VERV | Dorval Allison Chief Financial Officer | 554 | $11.45 | $6,343 | 7,810 (Direct) | View |
| 2022-12-01 Sale | 2022-12-02 5:00 pm | Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO | 865 | $22.95 | $19,852 | 6,629 (Direct) | View |
| 2022-11-29 Sale | 2022-12-01 5:00 pm | Verve Therapeutics Inc. | VERV | Dorval Allison Chief Financial Officer | 554 | $22.1 | $12,243 | 7,811 (Direct) | View |
| 2022-11-04 Sale | 2022-11-08 5:51 pm | Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner | 48,583 | $31.14 | $1,512,806 | 4,308,630 (Indirect) | View |
| 2022-11-04 Sale | 2022-11-08 5:04 pm | Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. Alphabet Inc. Member of 10% Group | 97,166 | $31.14 | $3,025,611 | 4,308,630 (Indirect) | View |
| 2022-11-02 Sale | 2022-11-04 5:58 pm | Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner | 78,220 | $33.95 | $2,655,330 | 4,386,850 (Indirect) | View |
| 2022-11-02 Sale | 2022-11-04 4:16 pm | Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. Alphabet Inc. Member of 10% Group | 156,440 | $33.95 | $5,310,658 | 4,386,850 (Indirect) | View |
| 2022-10-31 Sale | 2022-11-02 9:02 pm | Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner | 85,659 | $37.95 | $3,250,496 | 4,472,510 (Indirect) | View |
| 2022-10-31 Sale | 2022-11-02 4:25 pm | Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. Alphabet Inc. Member of 10% Group | 171,319 | $37.95 | $6,501,031 | 4,472,510 (Indirect) | View |
| 2022-10-28 Sale | 2022-11-01 5:00 pm | Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO | 10,000 | $39.9 | $399,000 | 93,624 (Direct) | View |
| 2022-10-03 Sale | 2022-10-05 5:00 pm | Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer | 50,000 | $33.65 | $1,682,622 | 778,828 (Indirect Direct) | View |
| 2022-09-23 Sale | 2022-09-27 5:00 pm | Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO | 60,000 | $35.34 | $2,120,392 | 126,822 (Direct) | View |
| 2022-08-10 Sale | 2022-08-11 5:00 pm | Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer | 50,000 | $29.9 | $1,495,000 | 807,258 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-04-01 Exercise | 2024-04-03 5:00 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Nickerson Joan Chief Administrative Officer | 3,315 | $0 | 18,604 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:30 pm | N/A 2034-02-13 | Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks | 186,000 | $0 | 186,000 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:30 pm | N/A 2034-02-13 | Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer | 658,000 | $0 | 658,000 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:30 pm | N/A 2034-02-13 | Verve Therapeutics Inc. | VERV | Nickerson Joan Chief Administrative Officer | 149,000 | $0 | 149,000 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:30 pm | N/A 2034-02-13 | Verve Therapeutics Inc. | VERV | Fiedorek Fred T. Chief Medical Officer | 112,000 | $0 | 112,000 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:30 pm | N/A 2034-02-13 | Verve Therapeutics Inc. | VERV | Dorval Allison Chief Financial Officer | 225,000 | $0 | 225,000 (Direct) | View |
| 2024-02-14 Option Award | 2024-02-16 4:30 pm | N/A 2034-02-13 | Verve Therapeutics Inc. | VERV | Bellinger Andrew Chief Scientific Officer | 225,000 | $0 | 225,000 (Direct) | View |
| 2022-11-07 Ownership | 2024-02-09 5:00 pm | N/A N/A | Verve Therapeutics Inc. | VERV | ADELMAN BURT A Director | 409,626 | $0 | 428,326 (Indirect) | View |
Ownership | 2023-12-05 4:50 pm | N/A N/A | Verve Therapeutics Inc. | VERV | GV 2023 GP L.L.C. GV 2023 GP L.P. GV 2023 L.P. Alphabet Inc. Member of 10% Group | 0 | $0 | 1,800,000 (Indirect) | View |
| 2023-11-29 Exercise | 2023-12-01 4:30 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Dorval Allison Chief Financial Officer | 1,875 | $0 | 7,810 (Direct) | View |
| 2023-09-18 Option Award | 2023-09-19 5:05 pm | N/A 2033-09-17 | Verve Therapeutics Inc. | VERV | Fiedorek Fred T. Chief Medical Officer | 180,000 | $0 | 180,000 (Direct) | View |
| 2023-06-15 Option Award | 2023-06-20 5:00 pm | N/A 2033-06-14 | Verve Therapeutics Inc. | VERV | MacLean Michael F Director | 26,642 | $0 | 26,642 (Direct) | View |
| 2023-06-15 Option Award | 2023-06-20 5:00 pm | N/A 2033-06-14 | Verve Therapeutics Inc. | VERV | Cumbo Alexander Director | 26,642 | $0 | 26,642 (Direct) | View |
| 2023-06-15 Option Award | 2023-06-20 5:00 pm | N/A 2033-06-14 | Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner | 26,642 | $0 | 26,642 (Direct) | View |
| 2023-06-15 Option Award | 2023-06-20 5:00 pm | N/A 2033-06-14 | Verve Therapeutics Inc. | VERV | ADELMAN BURT A Director | 26,642 | $0 | 26,642 (Direct) | View |
| 2023-06-15 Option Award | 2023-06-20 5:00 pm | N/A 2033-06-14 | Verve Therapeutics Inc. | VERV | COATS LONNEL Director | 26,642 | $0 | 26,642 (Direct) | View |
| 2023-06-15 Option Award | 2023-06-20 5:00 pm | N/A 2033-06-14 | Verve Therapeutics Inc. | VERV | Mikhail Sheila Director | 26,642 | $0 | 26,642 (Direct) | View |
Ownership | 2023-02-23 5:00 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Nickerson Joan Chief Administrative Officer | 0 | $0 | 242,940 (Direct) | View |
| 2023-02-14 Option Award | 2023-02-16 5:00 pm | N/A 2033-02-13 | Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO | 182,800 | $0 | 182,800 (Direct) | View |
| 2023-02-14 Option Award | 2023-02-16 5:00 pm | N/A 2033-02-13 | Verve Therapeutics Inc. | VERV | Dorval Allison Chief Financial Officer | 182,800 | $0 | 182,800 (Direct) | View |
| 2023-02-14 Option Award | 2023-02-16 5:00 pm | N/A 2033-02-13 | Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer | 550,200 | $0 | 550,200 (Direct) | View |
| 2023-02-14 Option Award | 2023-02-16 5:00 pm | N/A 2033-02-13 | Verve Therapeutics Inc. | VERV | MacLean Michael F Director | 7,000 | $0 | 7,000 (Direct) | View |
| 2023-02-14 Option Award | 2023-02-16 5:00 pm | N/A 2033-02-13 | Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks | 182,800 | $0 | 182,800 (Direct) | View |
| 2022-12-14 Exercise | 2022-12-16 5:00 pm | N/A 2030-09-15 | Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO | 36,000 | $0 | 222,623 (Direct) | View |
| 2022-12-14 Exercise | 2022-12-16 5:00 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO | 36,000 | $2.87 | 222,623 (Direct) | View |
| 2022-11-29 Exercise | 2022-12-01 5:00 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Dorval Allison Chief Financial Officer | 1,875 | $0 | 7,811 (Direct) | View |
| 2022-11-04 Other | 2022-11-08 5:51 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner | 48,583 | $0 | 4,308,630 (Indirect) | View |
| 2022-11-04 Other | 2022-11-08 5:04 pm | N/A N/A | Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. Alphabet Inc. Member of 10% Group | 48,583 | $0 | 4,308,630 (Indirect) | View |
| 2022-11-02 Other | 2022-11-04 5:58 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner | 78,220 | $0 | 4,386,850 (Indirect) | View |
| 2022-11-02 Other | 2022-11-04 4:16 pm | N/A N/A | Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. Alphabet Inc. Member of 10% Group | 78,220 | $0 | 4,386,850 (Indirect) | View |
| 2022-10-31 Other | 2022-11-02 9:02 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Yeshwant Krishna Director 10% Owner | 85,660 | $0 | 4,472,510 (Indirect) | View |
| 2022-10-31 Other | 2022-11-02 4:25 pm | N/A N/A | Verve Therapeutics Inc. | VERV | GV 2017 GP L.L.C. GV 2017 GP L.P. GV 2017 L.P. GV 2019 GP L.L.C. GV 2019 GP L.P. GV 2019 L.P. Alphabet Inc. Member of 10% Group | 85,660 | $0 | 4,472,510 (Indirect) | View |
| 2022-10-28 Exercise | 2022-11-01 5:00 pm | N/A 2029-09-16 | Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO | 10,000 | $0 | 93,624 (Direct) | View |
| 2022-10-28 Exercise | 2022-11-01 5:00 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO | 10,000 | $1.48 | 93,624 (Direct) | View |
| 2022-10-03 Exercise | 2022-10-05 5:00 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer | 50,000 | $1.39 | 778,828 (Direct) | View |
| 2022-10-03 Exercise | 2022-10-05 5:00 pm | N/A 2029-04-14 | Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer | 50,000 | $0 | 778,828 (Direct) | View |
| 2022-09-23 Exercise | 2022-09-27 5:00 pm | N/A 2029-09-16 | Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO | 60,000 | $0 | 126,822 (Direct) | View |
| 2022-09-23 Exercise | 2022-09-27 5:00 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Bellinger Andrew CSO & CMO | 60,000 | $1.48 | 126,822 (Direct) | View |
| 2022-08-25 Exercise | 2022-08-29 5:00 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks | 51,203 | $1.39 | 446,786 (Direct) | View |
| 2022-08-25 Exercise | 2022-08-29 5:00 pm | N/A 2028-11-07 | Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks | 95,787 | $0 | 446,786 (Direct) | View |
| 2022-08-25 Exercise | 2022-08-29 5:00 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks | 10,835 | $2.87 | 446,786 (Direct) | View |
| 2022-08-25 Exercise | 2022-08-29 5:00 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Ashe Andrew D. See Remarks | 33,749 | $1.48 | 446,786 (Direct) | View |
| 2022-08-10 Exercise | 2022-08-11 5:00 pm | N/A N/A | Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer | 50,000 | $1.39 | 807,258 (Direct) | View |
| 2022-08-10 Exercise | 2022-08-11 5:00 pm | N/A 2029-04-14 | Verve Therapeutics Inc. | VERV | Kathiresan Sekar Chief Executive Officer | 50,000 | $0 | 807,258 (Direct) | View |
| 2022-08-08 Option Award | 2022-08-09 5:05 pm | N/A 2032-08-07 | Verve Therapeutics Inc. | VERV | COATS LONNEL Director | 31,000 | $0 | 31,000 (Direct) | View |